Pharmacologic treatment of type 2 diabetic dyslipidemia

Pharmacotherapy

Volumn 24, Issue 12 I, 2004, Pages 1692-1713

  Moon, Yong S K ^a,b   Kashyap, Moti L ^b,c  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetic dyslipidemia; Lipid regulating drugs; Pharmacologic treatment; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYTOCHROME P450 INHIBITOR; DIGOXIN; DIURETIC AGENT; ESTROGEN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ABDOMINAL PAIN; ANEMIA; ATHEROSCLEROSIS; BLEEDING; BONE MARROW APLASIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC DYSLIPIDEMIA; DIARRHEA; DIET; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; FATIGUE; FLUSHING; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPATITIS; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPERTENSION; HYPOTENSION; INSOMNIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MORTALITY; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PERIPHERAL NEUROPATHY; PRURITUS; RASH; RECTUM HEMORRHAGE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN BRUISING; SMOKING; STOMACH PAIN; SUSTAINED DRUG RELEASE; TACHYCARDIA; THROMBOCYTOPENIA; TIMED DRUG RELEASE; VEIN THROMBOSIS; VIVID DREAM; VOMITING;

ANTILIPEMIC AGENTS; CLINICAL TRIALS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GUIDELINES; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; RISK FACTORS;

EID: 9644307857     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.17.1692.52340     Document Type: Review

References (108)

1. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-71.
2. Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol 1999;83:F17-21.
3. Taskinen MR. Strategies for the management of diabetic dyslipidemia. Drugs 1999;58(suppl 1):47-51.
4. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 1998;21:69-75.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
7. Haffner S. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:160-78.
8. National Cholesterol Education Program (NCEP) Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-22.
10. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 1997;20:614-20.
11. Goldberg RB, Mellies, MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-19.
12. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
13. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
15. Hoogwerf BJ, Waness A, Cressman M, et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the post coronary artery bypass graft trial. Diabetes 1999;48:1289-94.
16. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki heart study. Diabetes Care 1992;15:820-5.
17. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.
18. Steiner G, Stewart D, Hosking JD, Donald J, for the DAIS Project Group. Baseline characteristics of the study population in the diabetes atherosclerosis intervention study (DAIS). Am J Cardiol 1999;84:1004-10.
19. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001;357:905-10.
20. Robins SJ, Collins D, Wittes JT, et al, for the Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.
21. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001;111:633-42.
22. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140:650-8.
23. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the national cholesterol education program. Adult treatment panel III guidelines. Circulation 2004;110:227-39.
24. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association task force on risk reduction. Circulation 1997;95:1683-5.
25. American Diabetes Association. Nutrition recommendation and principles for people with diabetes mellitus. Diabetes Care 2001;24(suppl 1):S44-7.
26. American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care 2001;24(suppl 1):S51-5.
27. Taskinen MR, Kuusi T, Helve E, et al. Insulin therapy induces anti-atherogenic changes of serum lipoproteins in non-insulin-dependent diabetes. Arteriosclerosis 1988;8:168-77.
28. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
29. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes. Lancet 1998;352:854-65.
30. Bristol-Myers Squibb Company. Glucophage (metformin) package insert. Princeton, NJ; 2001.
31. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102:99-110.
32. Klepser TB, Kelly MW. Metformin hydrochloride: an antihyperglycemic agent. Am J Health-Syst Pharm 1997;54:893-903.
33. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-49.
34. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, for the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23.
35. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
36. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11.
37. Fruchart JC. PPAR and cardiovascular risk. J Cardiovasc Risk 2001;8:185-6.
38. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11.
39. Kaplan F, Al-Majali K, Betteridge DJ. PPARs, insulin resistance and type 2 diabetes. J Cardiovasc Risk 2001;8:211-17.
40. Takeda Chemical Industries. Actos (pioglitazone) package insert. Osaka, Japan; 2000.
41. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, for the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-11.
42. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25:517-23.
43. GlaxoSmithKline. Avandia (rosiglitazone) package insert. Research Triangle Park, NC; 2001.
44. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, for the Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32.
45. Phillips L, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, for the Rosiglitazone Clinical Trials Study Group. Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15.
46. Knopp RH. Drug therapy: drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
47. Wong ND, Kashyap ML. Cholesterol and lipids. In: Wong ND, Black HR, Gardin JM, eds. Preventive cardiology. New York: McGraw-Hill, 2000:7,165-93.
48. Sankyo Pharma Inc. Welchol (colesevelam) package insert. New York, NY; 2000.
49. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002;11:1587-604.
50. Merck-Schering-Plough Pharmaceuticals. Zetia (ezetimibe) package insert. North Wales, PA; 2002.
51. Andrx Laboratories, Inc. Altocor (lovastatin extended-release) package insert. Weston, FL; 2002.
52. AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin) package insert. Wilmington, DE; 2003.
53. National Cholesterol Education Program (NCEP) Expert Panel. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): final report. Circulation 2002;106:3143-421.
54. Merck & Co., Inc. Mevacor (lovastatin) package insert. Whitehouse Station, NJ; 2002.
55. Merck & Co., Inc. Zocor (simvastatin) package insert. Whitehouse Station, NJ; 2002.
56. Pfizer Parke-Davis, Division of Pfizer Inc. Lipitor (atorvastatin) package insert. New York, NY; 2002.
57. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study - a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41.
58. Copher HR, Stewart RD. Daily dosing versus alternate-day dosing of simvastatin in patients with hypercholesterolemia. Pharmacotherapy 2002;22:1110-16.
59. Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999;83:1135-7.
60. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000;23:197-213.
61. Tomlinson B, Chan P, Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging 2001;18:665-83.
62. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22:441-57.
63. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Pharmacoepidemiology 2002;36:288-95.
64. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8.
65. Henney J. Elevated cholesterol treatment. JAMA 2000;284:685.
66. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900.
67. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-60.
68. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24.
69. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.
70. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
71. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-75.
72. Zhu D, Ganji SH, Kamanna VS, Kashyap ML. Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. Atherosclerosis 2002;164:221-8.
73. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes: a meta-analysis. Diabetes Care 1998;21:494-500.
74. Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease: AHA scientific statement. Circulation 2002;106:2747-57.
75. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000;2:36-46.
76. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apoprotein A-I but not cholesterol ester by Hep G2 cells: implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8.
77. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol 1999;19:1051-9.
78. Ganji SH, Tavintharan S, Zhu D, Kamanna VS, Kashyap ML. Niacin non-competitively inhibits hepatocyte diacylglycerol acyltransferase, a key enzyme for triglyceride synthesis [abstr]. Arterioscler Thromb Vasc Biol 2002;22:878A.
79. Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 2001;3:74-82.
80. Sakai T, Kamanna VS, Kashyap ML. Niacin but not gemfibrozil increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2001;21:1783-9.
81. Kashyap ML. Mechanistic studies of high-density lipoproteins. Am J Cardiol 1998;82:U42-8.
82. Superko HR. What can we learn about dense low-density lipoprotein and lipoprotein particles from clinical trials. Curr Opin Lipidol 1996;7:363-8.
83. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997;157:1170-6.
84. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
85. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
86. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein. N Engl J Med 1990;323:1289-98.
87. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000;86(suppl):L51-6.
88. Molnar G, Berge K, Rosevear J, et al. The effect of nicotinic acid in diabetes mellitus. Metabolism 1964;13:181-90.
89. Kahn SE, Beard JC, Schwartz MW, et al. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-8.
90. Grundy SM, Vega GL, McGovern ME, et al, for the Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002;162:1568-76.
91. Elam MB, Hunninghake DB, Davis KB, et al, for the ADMIT Investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 2000;284:1263-70.
92. Kane MP, Hamilton RA, Addesse E, Busch RS, Bakst G. Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. Pharmacotherapy 2001;21:1473-8.
93. Kos Pharmaceuticals, Inc. Niaspan (niacin extended-release) package insert. Miami, FL; 2003.
94. Goldberg A, Alagona P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5.
95. Guyton JR, Blazing BA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-gemfibrozil study group. Arch Intern Med 2000;160:1177-84.
96. Hodis HN, Mack WJ, Lobo R. Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. Curr Atheroscler Rep 2002;4:52-8.
97. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
98. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
99. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-8.
100. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA 2002;288:2432-40.
101. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
102. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
103. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
104. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorrheologic parameter in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87:44-8.
105. Bairaktari ET, Tzallas CS, Tsimichodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999;6:113-16.
106. Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 2000;56:631-5.
107. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
108. Snow V, Aronson MD, Hornbake R, Mottur-Pilson C, Weiss KB. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140:644-9.